A randomised controlled trial to evaluate the effect of gloves containing silver fibre on burden caused by Raynaud's phenomenon in patients with systemic sclerosis

Published: 04-03-2019 Last updated: 19-03-2025

To determine the efficacy of silver enhanced gloves in decreasing burden of Raynaud*s phenomenon in patients with systemic sclerosis.

Ethical review Approved WMO **Status** Recruitment stopped

Health condition type Autoimmune disorders

Study type Interventional

Summary

ID

NL-OMON55595

Source

ToetsingOnline

Brief title

HANDS ON

Condition

Autoimmune disorders

Synonym

Raynaud s phenomenon, scleroderma

Research involving

Human

Sponsors and support

Primary sponsor: Leids Universitair Medisch Centrum

Source(s) of monetary or material Support: Afdelingsfonds afd. Reumatologie LUMC

Intervention

Keyword: Microangiopathy, Raynaud s phenomenon, Silver gloves, Systemic sclerosis

Outcome measures

Primary outcome

The primary endpoints of this study are the Raynaud Condition Score and the VAS for burden caused by Raynaud*s.

Secondary outcome

Secondary endpoints include frequency and duration of Raynaud*s attacks and a VAS for warmth of the hands as documented by the patients in a web-based log, the degree of microangiopathy as assessed by Nailfold Capillary Microscopy (NCM), the number of incident digital ulcers (DU) and the Scleroderma Health Assessment Questionnaire (SHAQ).

Study description

Background summary

For over a decade, adults suffering from Raynaud*s phenomenon secondary to systemic sclerosis, have been supplied with textiles (gloves, socks, shirts and pants) which contain silver fibres. In general, patients state to experience benefit from wearing these cloths. However, no substantial research has been done to provide objective evidence supporting the hypothesis that silver fibre enhanced textiles increase microcirculation and doing so, increase body temperature, decrease feelings of cold and decrease complications of impaired microcirculation including complaints of Raynaud*s phenomenon and digital ulcers. Therefore, this study aims to evaluate the benefits of silver fibre enhanced gloves in patients with Raynaud*s phenomenon secondary to systemic

sclerosis.

Study objective

To determine the efficacy of silver enhanced gloves in decreasing burden of Raynaud*s phenomenon in patients with systemic sclerosis.

Study design

Double-blind, randomised, cross-over trial. The trial is designed as a cross over trial to account for interindividual differences, weather changes during the trial period and influences of associations of the patients related to the colour of the gloves.

Intervention

The study will be a double-blinded study on 100 adult patients with systemic sclerosis. All patients will wear both normal gloves and gloves containing silver fibres, each during a period of 6 weeks. Each type of gloves will be provided in 2 different colours. Patients will be randomised to: group I: starting with orange gloves containing silver fibers, followed by green gloves without silver fibers; group II: starting with orange gloves without silver fibers, followed by green gloves with silver fibers; group 3: starting with green gloves without silver fibers; group 4: starting with green gloves without silver fibers, followed by orange gloves with silver fibers.

Study burden and risks

Participation in this study has several associated burdens:

- Three additional study visits will be scheduled. These will take approximately 30-45 minutes and include completing the SHAQ, inspection of the hands and nailfoldcapillaroscopy examination.
- Participants are requested to complete an online questionnaire three times per week to document their complaints while wearing the gloves.
- Because the gloves used in the study will be dyed, wearing of the gloves could cause an allergic reaction to those who have a hypersensitivity to dyeing products.
- As the benefit of gloves containing silver threads has not been evaluated thus far, risks directly related to the intervention are not clear. In case of worsening of symptoms, possibly related to study gloves, participation will be ended.
- Patients will be offered reimbursement of travel costs.

Contacts

Public

Leids Universitair Medisch Centrum

Albinusdreef 2 Leiden 2333ZA NL

Scientific

Leids Universitair Medisch Centrum

Albinusdreef 2 Leiden 2333ZA NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

- -Age * 18 years
- -Diagnosis of Systemic sclerosis according to ACR/EULAR (American College of Rheumatology/European League Against Rheumatism) 2013 classification criteria (total score of * 9, including a score of 3 for the RP item)
- -Raynaud*s attack frequency of at least 4 attacks per week on * 3 different days and a Raynaud Condition score (RCS) at baseline of at least 34 (on a scale of 0-100)
- -Vasoactive medication (Ca antagonists, ERA, PDE5 inhibitors) should be stable in the 2 weeks prior to the start of the trial
- -written informed consent

Exclusion criteria

- Past history of sympathectomy for Raynaud*s phenomenon
- Current treatment with iloprost, or iloprost infusion < 6 weeks prior to screening
- Known allergy for dyes used in textiles
- Known allergy for silver fibre

Study design

Design

Study type: Interventional

Intervention model: Crossover

Allocation: Randomized controlled trial

Masking: Double blinded (masking used)

Control: Active

Primary purpose: Treatment

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 08-12-2019

Enrollment: 85

Type: Actual

Medical products/devices used

Generic name: Best4Hands silver gloves 9% silver

Registration: Yes - CE intended use

Ethics review

Approved WMO

Date: 04-03-2019

Application type: First submission

5 - A randomised controlled trial to evaluate the effect of gloves containing silver ... 14-05-2025

Review commission: METC Leiden-Den Haag-Delft (Leiden)

metc-ldd@lumc.nl

Approved WMO

Date: 16-10-2020

Application type: Amendment

Review commission: METC Leiden-Den Haag-Delft (Leiden)

metc-ldd@lumc.nl

Approved WMO

Date: 26-03-2021

Application type: Amendment

Review commission: METC Leiden-Den Haag-Delft (Leiden)

metc-ldd@lumc.nl

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

ID: 20637

Source: Nationaal Trial Register

Title:

In other registers

Register ID

 CCMO
 NL67974.058.18

 Other
 Trial NL7904

 OMON
 NL-OMON20637

Study results

Date completed: 11-06-2021

Actual enrolment: 85

Summary results

Trial is onging in other countries